Once-daily LIXIANA®(edoxaban) Is Now Available

Daiichi Sankyo Hong Kong is proud to announce the launch of our new oral, direct factor Xa inhibitor, LIXIANA ® (edoxaban) in Hong Kong. A new
oral, once-daily anticoagulant, LIXIANA® (edoxaban) offers the combined benefits of once daily dosing and superior safety profile. Its efficacy and
safety have been well demonstrated in two phrase 3 clinical trials, ENGAGE AF-TIMI 48 and Hokusai-VTE. 1,2


LIXIANA® (edoxaban) comes in three strengths, namely 60mg x 28’s, 30mg x28’s, 15mg x 14’s to meet different patients need.


LIXIANA® (edoxaban) has now been marketed in many countries worldwide and is indicated for: 3

 -   

Prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF)

 -    Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and for the prevention of recurrent DVT and PE following initial treatment for DVT and /or PE


For more information, please visit: http://www.daiichisankyo.com.hk/


References

1 Giugliano R, et al. N Engl J Med. 2013;369(22):2093-104

 

2 Buller H, et al. N Engl J Med. 2013;369(15):1406-15

 

3 LIXIANA Hong Kong Package Insert Sep 2016